Last reviewed 2026-04-20 · How we verify

Gewodin (FAMPROFAZONE)

Phase 2 active Small molecule

Gewodin (generic name: FAMPROFAZONE) is a famprofazone drug. It is currently in Phase 2 development.

Gewodin works by binding to the nuclear receptor subfamily 2 group E member 1, influencing gene expression and cellular processes.

Gewodin, also known as famprofazone, is a small molecule drug that targets the nuclear receptor subfamily 2 group E member 1. Its exact commercial status is unknown, but it is classified as a famprofazone drug class. Gewodin's mechanism of action and approved indications are not well-documented, and it has not received FDA approval. Further research is needed to understand its potential therapeutic applications and safety considerations.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FAMPROFAZONE
Drug class	famprofazone
Target	Nuclear receptor subfamily 2 group E member 1
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells have a special switch that controls how they work. Gewodin is like a key that fits into this switch, turning it on or off to affect how your cells behave. This can help with various health issues, but more research is needed to understand exactly how it works and what benefits it can provide.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gewodin CI brief — competitive landscape report
Gewodin updates RSS · CI watch RSS

Frequently asked questions about Gewodin

What is Gewodin?

Gewodin (FAMPROFAZONE) is a famprofazone drug.

How does Gewodin work?

Gewodin works by binding to the nuclear receptor subfamily 2 group E member 1, influencing gene expression and cellular processes.

What is the generic name of Gewodin?

FAMPROFAZONE is the generic (nonproprietary) name of Gewodin.

What drug class is Gewodin in?

Gewodin belongs to the famprofazone class. See all famprofazone drugs at /class/famprofazone.

What development phase is Gewodin in?

Gewodin is in Phase 2.

What does Gewodin target?

Gewodin targets Nuclear receptor subfamily 2 group E member 1 and is a famprofazone.

Drug class: All famprofazone drugs
Target: All drugs targeting Nuclear receptor subfamily 2 group E member 1
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing